daw
11-06-2005, 01:10 AM
The following article was posted on the Johns Hopkins Barrett's discussion board. The article was released on Friday, October 31st regarding Barrx and the Halo360 treatment.
Data Evaluating Safety and Efficacy of the HALO360 System in Treating Barrett's Esophagus Presented at the American College of Gastroenterology Annual Meeting Studies Show 100% Clearance Rates for Barrett's Esophagus with Low Grade Dysplasia
BARRX Medical, Inc. today announced the results of a study presented by Virender K. Sharma, M.D. of the Mayo Clinic in Arizona, evaluating the safety, tolerability and effectiveness of the HALO360 System in the treatment of Barrett's esophagus with low grade dysplasia (LGD). The study results, presented at the American College of Gastroenterology Annual Meeting, October 28 thru November 2, 2005, demonstrate that all patients enrolled and treated have achieved complete resolution of LGD, a precancerous condition affecting the lining of the esophagus.
Nine male patients and one female patient with a mean age of 56 years and up to 6 cm of biopsy-proven Barrett's esophagus with LGD were enrolled in this study. After one or two treatments, histology from biopsies showed that all patients (100%) were completely free of LGD. The authors conclude that the HALO360 system allows for the complete and circumferential ablation of Barrett's esophagus with LGD without significant complications. As part of his presentation at the ACG, Dr. Sharma will also share data from a second study evaluating the use of the HALO360 system in patients with high grade dysplasia (HGD), an even more advanced disease state with a poor prognosis and limited treatment options. This data also shows encouraging results associated with HGD.
'As recently discussed in the Wall Street Journal, Barrett's esophagus is a serious health condition and a known precursor to esophageal adenocarcinoma, a dangerous form of cancer with a rapidly rising incidence in the United States,' said David S. Utley, M.D., Chief Medical Officer, BARRX Medical, Inc. 'Dr. Sharma's findings are an important addition to the rapidly accumulating set of data supporting the safety and efficacy of the HALO360 system in treating dysplastic and non-dysplastic Barrett's esophagus.'
"Patients who are diagnosed with Barrett's esophagus and either LGD or HGD are particularly at risk for cancer development," states Dr. Sharma. "Once dysplasia occurs, we must remain particularly vigilant for cancer for the lifetime of the patient. As with the precancerous colon polyp, it makes logical sense that if we can eliminate the Barrett's dysplasia completely and safely, we should do so in order to reduce the risk for developing cancer."
Approximately two million adults in the United States are under regular surveillance, endoscopy with biopsy, for Barrett's esophagus. Caused by chronic GERD (gastroesophageal reflux disease), Barrett's esophagus is a precancerous condition affecting the lining of the esophagus, the muscular tube that carries food, liquids and saliva from the mouth to the stomach. Barrett's esophagus can lead to a dangerous type of cancer called esophageal adenocarcinoma, which is currently the most rapidly rising cancer in the U.S. The HALO360 system, a second-generation ablation device, removes the thin layer of diseased esophageal tissue allowing the regrowth of normal cells.
Data Evaluating Safety and Efficacy of the HALO360 System in Treating Barrett's Esophagus Presented at the American College of Gastroenterology Annual Meeting Studies Show 100% Clearance Rates for Barrett's Esophagus with Low Grade Dysplasia
BARRX Medical, Inc. today announced the results of a study presented by Virender K. Sharma, M.D. of the Mayo Clinic in Arizona, evaluating the safety, tolerability and effectiveness of the HALO360 System in the treatment of Barrett's esophagus with low grade dysplasia (LGD). The study results, presented at the American College of Gastroenterology Annual Meeting, October 28 thru November 2, 2005, demonstrate that all patients enrolled and treated have achieved complete resolution of LGD, a precancerous condition affecting the lining of the esophagus.
Nine male patients and one female patient with a mean age of 56 years and up to 6 cm of biopsy-proven Barrett's esophagus with LGD were enrolled in this study. After one or two treatments, histology from biopsies showed that all patients (100%) were completely free of LGD. The authors conclude that the HALO360 system allows for the complete and circumferential ablation of Barrett's esophagus with LGD without significant complications. As part of his presentation at the ACG, Dr. Sharma will also share data from a second study evaluating the use of the HALO360 system in patients with high grade dysplasia (HGD), an even more advanced disease state with a poor prognosis and limited treatment options. This data also shows encouraging results associated with HGD.
'As recently discussed in the Wall Street Journal, Barrett's esophagus is a serious health condition and a known precursor to esophageal adenocarcinoma, a dangerous form of cancer with a rapidly rising incidence in the United States,' said David S. Utley, M.D., Chief Medical Officer, BARRX Medical, Inc. 'Dr. Sharma's findings are an important addition to the rapidly accumulating set of data supporting the safety and efficacy of the HALO360 system in treating dysplastic and non-dysplastic Barrett's esophagus.'
"Patients who are diagnosed with Barrett's esophagus and either LGD or HGD are particularly at risk for cancer development," states Dr. Sharma. "Once dysplasia occurs, we must remain particularly vigilant for cancer for the lifetime of the patient. As with the precancerous colon polyp, it makes logical sense that if we can eliminate the Barrett's dysplasia completely and safely, we should do so in order to reduce the risk for developing cancer."
Approximately two million adults in the United States are under regular surveillance, endoscopy with biopsy, for Barrett's esophagus. Caused by chronic GERD (gastroesophageal reflux disease), Barrett's esophagus is a precancerous condition affecting the lining of the esophagus, the muscular tube that carries food, liquids and saliva from the mouth to the stomach. Barrett's esophagus can lead to a dangerous type of cancer called esophageal adenocarcinoma, which is currently the most rapidly rising cancer in the U.S. The HALO360 system, a second-generation ablation device, removes the thin layer of diseased esophageal tissue allowing the regrowth of normal cells.